院前单次肌钙蛋白检测排除非ST段抬高型急性冠脉综合征的随机试验
该随机试验在荷兰五个救护车区域纳入HEAR评分≤3分的疑似NSTE-ACS患者,比较院前POC肌钙蛋白排除策略与直接转诊急诊科。结果显示院前策略显著降低30天医疗费用,且两组30天MACE发生率相当,在排除ACS人群中MACE均很低。
要点
- HEAR评分≤3分的疑似NSTE-ACS患者可采用院前POC肌钙蛋白排除策略。
- 院前策略显著降低30天医疗费用,平均差€611(95%CI 353-869;P<0.001)。
- 两组30天MACE发生率相当,排除ACS人群MACE很低。
核心结论
- 在低危疑似NSTE-ACS患者中,院前POC肌钙蛋白排除策略显著降低医疗费用,且两种策略的MACE发生率均低。
研究设计与样本
- 研究者发起的随机临床试验,在荷兰五个救护车区域开展,共随机863例HEAR评分≤3分的疑似NSTE-ACS患者。
- 样本量计算基于主要结局30天医疗费用。
主要发现
- 院前策略组医疗费用为€1349 ± €2051,急诊科策略组为€1960 ± €1808,平均差€611(95%CI 353-869;P<0.001)。
- 总人群中30天MACE:院前策略组3.9%(17/434),急诊科策略组3.7%(16/429),P=0.89。
- 排除ACS人群中30天MACE:院前策略组0.5%(2/419),急诊科策略组1.0%(4/417),风险差-0.5%(95%CI -1.6%-0.7%;P=0.41)。
关键数值与推荐
- 疑似NSTE-ACS患者HEAR评分≤3分可考虑院前POC肌钙蛋白排除策略。
- 主要结局为30天医疗费用,次要结局为30天MACE(包括ACS、非计划血运重建或全因死亡)。
临床怎么用
- 对于HEAR评分≤3分的疑似NSTE-ACS患者,院前POC肌钙蛋白排除策略可降低医疗费用且不增加30天MACE风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: Patients with suspected non-ST-segment elevation acute coronary syndrome (NSTE-ACS) are routinely transferred to the emergency department (ED). A clinical risk score with point-of-care (POC) troponin measurement might enable ambulance paramedics to identify low-risk patients in whom ED evaluation is unnecessary. The aim was to assess safety and healthcare costs of a pre-hospital rule-out strategy using a POC troponin measurement in low-risk suspected NSTE-ACS patients. METHODS AND RESULTS: This investigator-initiated, randomized clinical trial was conducted in five ambulance regions in the Netherlands. Suspected NSTE-ACS patients with HEAR (History, ECG, Age, Risk factors) score ≤3 were randomized to pre-hospital rule-out with POC troponin measurement or direct transfer to the ED. The sample size calculation was based on the primary outcome of 30-day healthcare costs. Secondary outcome was safety, defined as 30-day major adverse cardiac events (MACE), consisting of ACS, unplanned revascularization or all-cause death. : A total of 863 participants were randomized. Healthcare costs were significantly lower in the pre-hospital strategy (€1349 ± €2051 vs. €1960 ± €1808) with a mean difference of €611 [95% confidence interval (CI): 353-869; P < 0.001]. In the total population, MACE were comparable between groups [3.9% (17/434) in pre-hospital strategy vs. 3.7% (16/429) in ED strategy; P = 0.89]. In the ruled-out ACS population, MACE were very low [0.5% (2/419) vs. 1.0% (4/417)], with a risk difference of -0.5% (95% CI -1.6%-0.7%; P = 0.41) in favour of the pre-hospital strategy. CONCLUSION: Pre-hospital rule-out of ACS with a POC troponin measurement in low-risk patients significantly reduces healthcare costs while incidence of MACE was low in both strategies. TRIAL REGISTRATION: Clinicaltrials.gov identifier NCT05466591 and International Clinical Trials Registry Platform id NTR 7346.
引用
- Camaro, Aarts, Adang, et al. Rule-out of non-ST-segment elevation acute coronary syndrome by a single, pre-hospital troponin measurement: a randomized trial. Eur Heart J. 2023. PMID: 36755110. doi:10.1093/eurheartj/ehad056
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。